Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Takeshi, Imaoka"'
Publikováno v:
The Lancet Diabetes & Endocrinology. 10:623-633
Publikováno v:
The Lancet Diabetes & Endocrinology. 10:634-644
Due to potential ethnic differences in the pathophysiology of type 2 diabetes, new therapeutics need to be evaluated in Japanese patients. We aimed to assess the safety and glycaemic efficacy of tirzepatide as an add-on treatment in Japanese patients
Autor:
Arihiro Kiyosue, Julia P. Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J. Heine
Publikováno v:
Diabetes, obesitymetabolism.
To assess the safety and efficacy of tirzepatide in people of East Asian descent based on age and BMI. .Data of participants enrolled in East Asian countries in the SURPASS-1, -3, -4, -5, J-mono, and J-combo Phase 3 clinical trials were included. Par
Autor:
Ikuro, Matsuba, Takehiro, Kawata, Miho, Ajima, Shinichi, Umezawa, Mizuki, Kaneshiro, Taro, Asakura, Hideo, Machimura, Tasuku, Sawa, Keiji, Tanaka, Hiroshi, Takeda, Takeshi, Imaoka, Akira, Kanamori
Publikováno v:
Diabetes Therapy. 13:265-274
MOSAIc was a multinational, non-interventional, prospective, observational cohort study designed to provide an understanding of the specific challenges associated with intensification of initial insulin therapy in patients with type 2 diabetes mellit
Publikováno v:
Diabetes Therapy. 11:2089-2104
We evaluated the efficacy and safety of ultra-rapid lispro (URLi) in comparison to lispro in a subgroup analysis of Japanese adults with type 1 diabetes mellitus from the phase 3 PRONTO-T1D trial. After an 8-week lead-in to optimize basal insulin tre
Publikováno v:
Diabetes Therapy
Introduction The aim of this study was to evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro in a subgroup analysis of Japanese adults with type 2 diabetes mellitus (T2DM) from the phase 3 PRONTO-T2D trial. Methods After an 8
Autor:
Momoha Koyanagi, Takeshi Imaoka, Tomotaka Shingaki, Aki Yoshikawa, Norika Oki, Kentaro Taki, Soshi Nagaoka, Kenichi Yoshizawa
Publikováno v:
Current Medical Research and Opinion. 36:947-958
Objective: To evaluate the long-term safety and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice.Methods: This prospective, non-interventional, multicenter, observ...
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Publikováno v:
Diabetes, obesitymetabolism. 24(2)
AIM To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Japanese participants with type 2 diabetes (T2D). METHODS This phase 1, double-blind, placebo-controlled, parallel-dose, multiple-ascendin
Autor:
Alena Strizek, Toshihiko Aranishi, Hiroshi Maegawa, Nobuhiro Arai, Zhihong Cai, Takeshi Imaoka, Yasushi Ishigaki
Publikováno v:
Diabetes Therapy
Introduction There are limited real-world data on the prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes mellitus (T2DM). Methods This was a retrospective analysis of the CoDiC® database of the Jap